&w=3840&q=100)
US visa update: B1/B2 interview waiver window cut from 48 to 12 months
Until now, applicants whose visas had expired within the past 48 months could apply for a renewal without attending an interview. That grace period will be reduced to 12 months under the new rules, as per revised guidance from the US Department of State.
Current policy till September 1, 2025):
From September 2, 2025):
The eligibility window is reduced drastically: only those whose previous B1/B2 visa expired within the past 12 months can apply without an interview.
What this means:
— Fewer people will now qualify for dropbox or waiver processing.
— More applicants will be required to appear for in-person interviews at consulates, increasing appointment demand and wait
The change will mean many more applicants will now need to schedule in-person appointments at US consulates, potentially straining already stretched visa processing systems in countries like India.
Notably, in 2023, over 700,000 B1/B2 (visitor) visa applications were processed for Indians by the US.
More face-to-face interviews ahead
For applicants used to the 'dropbox' route, this update could be a setback. The dropbox facility allowed people renewing certain visa types to simply submit documents without visiting a consulate. With the new 12-month expiry rule, only a smaller subset of applicants will now qualify.
The policy also grants US consular officers the discretion to call any applicant for an interview, regardless of eligibility under the waiver programme.
Fewer waivers, more checks
The B1/B2 category isn't the only one impacted. Students on F-1 visas and professionals on H-1B will also be asked to appear in person if their previous visa expired over 12 months ago—even if they previously qualified for a waiver.
Still, some categories remain eligible for interview waivers, including:
Children under 14
Adults over 79
Applicants for diplomatic and official visas such as A-1, A-2, G-1 to G-4, NATO, and TECRO E-1
Applicants renewing diplomatic or official visas
Mexican nationals with a Border Crossing Card/Foil, or applicants for B1/B2 visas applying from their country of residence without any past visa refusals or apparent ineligibility, may also be considered for a waiver.
New Visa Integrity Fee to be charged
Earlier this month, the Trump administration rolled out a new Visa Integrity Fee of $250 (around Rs 21,700). This fee applies to all non-immigrant visa categories and is collected at the time of visa approval—not during application.
The Department of State has said the fee applies to most major categories including tourist (B-2), business (B-1), student (F, M), work (H-1B), and exchange visitor (J) visas.
'There are no exemptions for these groups. The fee will be adjusted every year based on inflation,' said a consular note issued to applicants.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
India Today
an hour ago
- India Today
Thousands of Boeing fighter jet workers go on strike after rejecting contract offer
Boeing's defence operations faced disruptions on Monday as thousands of union workers went on strike, halting assembly lines for fighter jets and missile systems. The strike began after members of the International Association of Machinists and Aerospace Workers (IAM) District 837 overwhelmingly rejected Boeing's latest contract 3,200 workers have walked off the job in what marks their first strike in nearly 30 years. The affected workers, primarily based in the St. Louis region, are responsible for assembling and maintaining military aircraft, including the F-15 fighter jet and various missile systems. advertisementWORKERS TURN DOWN OFFERBoeing offered a 20% wage increase, a $5,000 signing bonus, and better retirement benefits in its final contract proposal. The company said the package would raise the average machinist's pay from $75,000 to more than $102,000 — a 40% increase when factoring in all proposed changes, according to union members rejected the offer, saying it fails to reflect their value or keep pace with increasing living costs."IAM District 837 members have spoken loud and clear—they deserve a contract that reflects their skill, dedication, and the critical role they play in our nation's defence," said Tom Boelling, directing business representative for the union. "We stand shoulder to shoulder with these working families as they fight for fairness and respect on the job," he added. BOEING ACTIVATES STRIKE PLANBoeing said it was disappointed by the outcome but added it was prepared for a strike and had contingency plans in place."We are prepared for a strike and have fully implemented our contingency plan to ensure our non-striking workforce can continue supporting our customers," said Dan Gillian, vice president at Boeing and senior executive at the St. Louis site, in a written the strike is expected to disrupt some defence manufacturing operations, Boeing CEO Kelly Ortberg downplayed the potential impact during an earnings call last week."We'll manage through this. I wouldn't worry too much about the implications of the strike. We'll manage our way through that," Ortberg Boeing defence walkout is the latest in a wave of labour actions across the aviation industry, driven by workforce shortages and demands for higher pay and better benefits. Union victories have become more common as skilled workers grow increasingly defence division accounted for roughly 30% of its $42 billion in revenue during the first half of the year. Last year, more than 32,000 Boeing machinists in the company's commercial airplane division walked off the job, frustrated by stalled contract talks. The seven-week strike, one of the largest in Boeing's history, ended in November after workers approved a new deal that included 38% pay increases over four years along with several quality-of-life improvements.- Ends
Time of India
an hour ago
- Time of India
Why Trump's threat is unlikely to wean India off Russian crude
AI photo NEW DELHI: Trump's latest threat is unlikely to affect India's decision to source crude from Moscow as long as it's cheaper than the alternatives. "We will go solely by the interest of our consumers and opt for the best option price-wise. If Russian crude works out cheaper than what we can get from other sources, why should we penalise our consumers?" said a senior government source who did not rule out the possibility of India exploring further discounts from Moscow in the light of Trump's threat. Sources said NSA Ajit Doval's visit to Russia, beginning Tuesday, will yield clarity on the geo-economic trilemma. The Centre has so far not made any move to wean off Indian oil refiners from Russian crude, which comes at a steep discount compared to purchases from west Asia or US. It has not just helped keep domestic pump prices lower, but also benefited European countries, which have been major buyers of diesel and jet fuel from India, sources said. Biz circles agree with Centre's criticism of Trump's latest diktat Business circles in New Delhi agreed with the Centre's criticism of Trump's latest diktat. "India's oil trade with Russia has taken place with full transparency and broad understanding with the US. One of the key reasons India stepped up Russian oil purchases was to help stabilise global oil markets after Western sanctions disrupted traditional supply chains. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo By maintaining diversified and affordable energy access, India contributed to preventing a global oil price shock. Trump's decision to raise tariffs on India citing oil trade is not only unjustified - it ignores market realities, misrepresents trade data, and undermines a key strategic partnership in the Indo-Pacific," trade research body GTRI said in a note. Interestingly, Trump's sudden bid to arm twist India into abandoning purchase of Russian crude follows declining purchase from Moscow because of sheer logic of markets. In May, India's crude petroleum imports from Russia fell almost 10% to $9.2 billion. Trump's latest comment is expected to create fresh uncertainty among American buyers, who are in talks with Indian exporters for placing orders for the busy Christmas season. The government's firm stand on farm and dairy is seen to have come as a blow for Trump, who had gone public over a dozen times claiming that India had agreed to slash tariffs. Shaken by the govt's steadfast opposition to blocking genetically modified American corn and soybean as well as its public rebuttal of claims over the US mediating a ceasefire during Operation Sindoor have hurt Trump's claim to have brokered several peace deals - one in each month of his second term as president. During the talks, negotiators had indicated the government's willingness to step up purchases of American oil, gas, fertilizer and defence equipment to improve the trade balance which is tilted in India's favour. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025
